Journey Medical reports Q3 EPS (9c), consensus (4c)

Reports Q3 revenue $17.63M, consensus $18.85M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “Our third quarter 2025 results reflect continued strong execution and accelerating commercial momentum, with revenue increasing 21% year-over-year to $17.6 million. Emrosi(TM) continues to drive growth, generating $4.9 million in net sales in the third quarter alone, supported by robust market adoption and payer access that continues to expand. We anticipate the growth of Emrosi and our established dermatology commercial infrastructure to generate significant operating leverage going forward.”